ArticleAustralasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists2026
Actionable medications in Australian Vietnam War veterans: Implications for pre-emptive pharmacogenetic testing.
Article in Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose of researchDescribe prescribing patterns in Australian Vietnam veterans, identify CYP2C19-metabolised medications using established pharmacogenetic (PGx) resources, characterise CYP2C19 profiles of veterans and assess the potential clinical impact of these medications.Major findingsAmong 283 veterans with CYP2C19 profiles, 256 reported current medications use, with a mean prescribed medication of 5.4. Of these, 89 veterans (34.7%) were prescribed at least one medication with CYP2C19 PGx recommendation. Notably, 52 veterans (58.4%) had CYP2C19 profiles that may be at risk of therapeutic failure or adverse effects. Prescribed medications also included six CYP2C19 inhibitors and one inducer, with potential to induce phenoconversion and impact drug metabolism.ConclusionVeterans experienced high levels of polypharmacy and frequently carried CYP2C19 phenotypes associated with increased risk of therapeutic failure or adverse effects. The presence of CYP2C19 inhibitors and inducers raises the potential for phenoconversion, where CYP2C19 profiles may be placed at risk. Given their similarities to the broader older population, these findings suggest that both groups may benefit from pre-emptive PGx testing. Furthermore, ongoing monitoring of drug-gene and drug-drug interactions remains essential to optimise medication safety and efficacy in these high-risk individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.